• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results

    4/30/25 8:00:00 AM ET
    $TLSI
    Medical Specialities
    Health Care
    Get the next $TLSI alert in real time by email

    Funding Anticipated to Accelerate Applications Already in Use and New Additional Potential Applications

    Anticipated Preferred Stock Exchange to Simplify Capital Structure

    Private Placement Expected to Fund Business to Profitability

    Healthcare Focused Long-term Investors Support Strategic Vision

    TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications, today announces preliminary financial results for Q1 2025 and that it has entered into a securities purchase agreement with certain investors for shares of its common stock to raise approximately $22.0 million in gross proceeds. Additionally, as further described below, the Company committed to commence an exchange offer with respect to its outstanding Series A Convertible Preferred Stock (the "Preferred Stock"), which is intended to simplify the Company's capital structure.

    Preliminary Unaudited First Quarter 2025 Financial Results

    Full financial results for the quarter ended March 31, 2025 are in the process of being finalized, however, initial and preliminary results show revenue, driven solely by the TriNav® Infusion System, of approximately $9.2 million for the first quarter of 2025. This represents growth of approximately 42% versus the first quarter of 2024.

    Private Placement

    The private placement is being led by Nantahala Capital and includes investments by Broadfin Holdings and additional healthcare-focused institutional investors. Canaccord Genuity is acting as the sole placement agent for the private placement.

    The Company will issue an aggregate of 5,500,000 shares of its common stock at a purchase price of $4.00 per share. The private placement is expected to close on or about May 2, 2025, subject to satisfaction of customary closing conditions. The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the "SEC") registering the resale of the shares of common stock issued in the private placement and intends to use the net proceeds from the private placement for working capital and general corporate purposes.

    The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities to be sold in the private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state or other applicable jurisdiction's securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions' securities laws.

    Simplifying the Capital Structure

    In connection with the private placement, TriSalus has entered into a Tender and Support Agreement with certain holders representing approximately 55% of outstanding shares of Preferred Stock. The Company has agreed to:

    • Launch a registered exchange offer pursuant to a registration statement on Form S-4 to be filed with the SEC to offer all preferred holders the opportunity to exchange their shares of Preferred Stock into a number of shares of common stock calculated based on a fixed value of $10.00 per share of Preferred Stock plus accrued dividends that would have accrued through August 10, 2027, divided by $4.00 per share; and
    • Convene a special meeting of stockholders to, among other things, vote on an amendment to the Certificate of Designations for the Preferred Stock that would (i) allow TriSalus to call and convert outstanding shares of Preferred Stock under specific terms and (ii) eliminate the conversion price reset provision currently scheduled for July 2027.

    The Company expects to launch the exchange offer by the end of the second quarter of 2025 and to hold the special meeting in the third quarter of 2025. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offering of the securities under the resale registration statement will only be made by means of a prospectus.

    About Preliminary Financial Results

    The preliminary results set forth above are unaudited, are based on management's initial review of the Company's results for the quarter ended March 31, 2025, and are subject to revision based upon the Company's quarter-end closing procedures. Actual results may differ materially from these preliminary unaudited results following the completion of quarter-end closing procedures, final adjustments or other developments arising between now and the time that the Company's financial results are finalized. In addition, these preliminary unaudited results are not a comprehensive statement of the Company's financial results for the quarter ended March 31, 2025, should not be viewed as a substitute for full, unaudited financial statements for the quarter ended March 31, 2025, and are not necessarily indicative of the Company's results for any future period.

    About TriSalus Life Sciences

    TriSalus Life Sciences® is an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors. The Company's platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company's two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD) approach to deliver a range of therapeutics: the TriNav® Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. The PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes. Nelitolimod, the Company's investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials support the hypothesis that nelitolimod delivered via the PEDD technology may have favorable immune effects within the liver and systemically. The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by the PEDD technology are commonly present as well. The Company is in the final stages of data completion for a number of phase 1 clinical trials and will begin exploring partnership opportunities for development.

    Where You Can Find Additional Information

    In connection with the Company's obligations under the securities purchase agreement and Support Agreement, the Company intends to file a registration statement on Form S-4 containing a proxy statement/prospectus, an exchange offer statement on Schedule TO (the "Schedule TO"), including an offer to exchange, a letter of transmittal and consent and related documents, and other documents concerning the proposed Exchange Offer and Special Meeting with the SEC. THE COMPANY URGES INVESTORS TO READ THE PROXY STATEMENT/PROSPECTUS, THE SCHEDULE TO AND THESE OTHER MATERIALS CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, THE EXCHANGE OFFER AND THE PROPOSED AMENDMENT. Investors may obtain free copies of the proxy statement/prospectus, Schedule TO (in each case, when available) and other documents filed by the Company with the SEC at the SEC's website at www.sec.gov. Free copies of these documents (when available) and the Company's other SEC filings are also available on the Company's website at https://investors.trisaluslifesci.com/financials/sec-filings.

    The Company and its directors, executive officers, certain members of management and certain employees may be deemed, under SEC rules, to be participants in the solicitation of proxies with respect to the proposed Exchange Offer and Special Meeting. Information regarding the Company's officers and directors is included in the Company's Definitive Proxy Statement on Schedule 14A with respect to its 2025 Annual Meeting of Stockholders, which we expect to file with the SEC on April 30, 2025. This document will be available free of charge at the SEC's website at www.sec.gov or by going to the Company's website at https://investors.trisaluslifesci.com/financials/sec-filings. Additional information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of proxies in connection with the proposed Special Meeting, and a description of their direct and indirect interests in the proposed Exchange Offer, Amendment and other items that may be presented at the Special Meeting, which may differ from the interests of the Company's stockholders generally, will be set forth in the proxy statement/prospectus when it is filed with the SEC.

    Forward Looking Statements

    Statements made in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward‐looking statements. Such statements include, but are not limited to, statements regarding the completion and timing of the private placement, the exchange offer and the special meeting, the approval and adoption of the amendment to the Certificate of Designations and the gross proceeds the Company expects to receive from the private placement; the anticipated use of proceeds from the private placement; the anticipated cash runway from the proceeds from the private placement; the Company's financial results for the three months ended March 31, 2025; the Company's belief as to the factors causing the financial results; the benefits and potential benefits of the Company's PEDD drug delivery technology, TriNav® system and nelitolimod investigational immunotherapy,, and the Company's ability to execute on its strategy. Risks that could cause actual results to differ from those expressed in these forward‐looking statements include risks associated with clinical development and regulatory approval of drug delivery and pharmaceutical product candidates, including that future clinical results may not be consistent with patient data generated during the Company's clinical trials, the cost and timing of all development activities and clinical trials, unexpected safety and efficacy data observed during clinical studies, the risks associated with the credit facility, including the Company's ability to remain in compliance with all its obligations thereunder to avoid an event of default, the risk that the Company will continue to raise capital through the issuance and sale of its equity securities to fund its operations, the risk that the Company will not be able to achieve the applicable revenue requirements to access additional financing under the credit facility, the risk that the Company will not become profitable on its expected timeline, if at all, the risk that the reported financial results will differ from the estimates provided in this press release, changes in expected or existing competition or market conditions, changes in the regulatory environment, unexpected litigation or other disputes, unexpected expensed costs, the ability for the Company to obtain the necessary approvals needed to consummate the exchange offer and adopt the Amendment, the timing and potential delays related to the special meeting and exchange offer, and other risks described in the Company's filings with the Securities and Exchange Commission under the heading "Risk Factors." All forward‐looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made except as required by law.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250430767814/en/

    For Media Inquiries:

    Jeremy Feffer, Managing Director

    LifeSci Advisors

    917.749.1494

    [email protected]

    For Investor Inquiries:

    James Young

    Chief Financial Officer

    847.337.0655

    [email protected]

    Get the next $TLSI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TLSI

    DatePrice TargetRatingAnalyst
    2/13/2025Buy
    Lake Street
    12/17/2024$10.00Overweight
    Cantor Fitzgerald
    11/11/2024$11.00Buy
    ROTH MKM
    10/25/2024$12.50Outperform
    Northland Capital
    9/16/2024$10.00Outperform
    Oppenheimer
    5/30/2024$12.00Buy
    Canaccord Genuity
    More analyst ratings

    $TLSI
    Financials

    Live finance-specific insights

    See more
    • TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance

      Company delivers 42% revenue growth year-over-year and strengthens balance sheet with $22 million gross proceeds from recent private placement Expands commercial footprint, and invests further in new applications for TriNav already in use Updates 2025 guidance to reflect strategic investment in our core liver market and new applications for PEDD Company to Host Conference Call and Webcast today at 8:00am ET TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results fo

      5/15/25 7:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call

      Conference Call and Webcast Scheduled for Thursday May 15, 2025 at 8:00 AM TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, announced today that it will host a conference call and webcast on Thursday May 15, 2025 at 8:00 AM eastern time to discuss its financial results for the quarter ended March 31, 2025. A press release detailing the results will be issued prior to the call. Parties interested in participating by phone should register using this online form. After registering for the web

      5/12/25 4:30:00 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update

      Revenues of $8.3 Million in Q4 and $29.4 Million for Full-Year 2024, Representing Growth of 44% And 59%, Respectively, Versus the Prior Year Periods Gross Margin of 85% and 86% for Q4 and Full-Year 2024 Reaffirmed 2025 Guidance of Greater than 50% Revenue Growth, Greater than 20% Reduction in Operating Expenses, Positive EBITDA, and Positive Cash flow in H2 2025 Management to host earnings conference call on March 27 at 8:00 a.m. EDT TriSalus Life Sciences Inc., (NASDAQ:TLSI), oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and with our inv

      3/27/25 7:30:00 AM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Young James Emmett was granted 13,175 shares, increasing direct ownership by 36% to 49,663 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      5/21/25 5:37:01 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • Chief of Research Cox Bryan F. was granted 15,722 shares and sold $24,678 worth of shares (4,764 units at $5.18), increasing direct ownership by 10% to 119,415 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      5/21/25 5:33:13 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • Chief of Clinical Operations Devlin Jodi was granted 24,131 shares and sold $24,678 worth of shares (4,764 units at $5.18), increasing direct ownership by 58% to 52,764 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      5/21/25 5:31:57 PM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $TLSI
    SEC Filings

    See more

    $TLSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance

      Company delivers 42% revenue growth year-over-year and strengthens balance sheet with $22 million gross proceeds from recent private placement Expands commercial footprint, and invests further in new applications for TriNav already in use Updates 2025 guidance to reflect strategic investment in our core liver market and new applications for PEDD Company to Host Conference Call and Webcast today at 8:00am ET TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results fo

      5/15/25 7:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call

      Conference Call and Webcast Scheduled for Thursday May 15, 2025 at 8:00 AM TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, announced today that it will host a conference call and webcast on Thursday May 15, 2025 at 8:00 AM eastern time to discuss its financial results for the quarter ended March 31, 2025. A press release detailing the results will be issued prior to the call. Parties interested in participating by phone should register using this online form. After registering for the web

      5/12/25 4:30:00 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results

      Funding Anticipated to Accelerate Applications Already in Use and New Additional Potential Applications Anticipated Preferred Stock Exchange to Simplify Capital Structure Private Placement Expected to Fund Business to Profitability Healthcare Focused Long-term Investors Support Strategic Vision TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and techn

      4/30/25 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by TriSalus Life Sciences Inc.

      10-Q - TriSalus Life Sciences, Inc. (0001826667) (Filer)

      5/15/25 7:54:52 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)

      5/15/25 7:34:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • SEC Form D filed by TriSalus Life Sciences Inc.

      D - TriSalus Life Sciences, Inc. (0001826667) (Filer)

      5/8/25 4:19:26 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by TriSalus Life Sciences Inc.

      SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

      12/4/24 4:00:06 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by TriSalus Life Sciences Inc.

      SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

      10/21/24 8:25:05 AM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    Leadership Updates

    Live Leadership Updates

    See more
    • TriSalus Life Sciences Announces Key Appointments to Board of Directors

      HealthCare Industry Veterans William Valle and Gary Gordon, M.D. add Strategic Expertise in Medical Devices, Reimbursement, and Pancreatic Cancers TriSalus Life Sciences® Inc. (NASDAQ:TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies and its investigational immunotherapy, today announced the appointment of two distinguished HealthCare Industry veterans to its Board of Directors. Mr. William J. Valle and Gary B. Gordon, M.D., Ph.D., joined the Company's Board of Directors, effective as of January 29, 2025. "We are thrilled to welcome William Valle and Dr. Ga

      2/3/25 4:05:00 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Announces Leadership Changes

      James Young Appointed Chief Financial Officer, Richard Marshak Appointed Chief Commercial Officer, Jodi Devlin Appointed Chief of Clinical Strategy and Operations TriSalus Life Sciences, Inc., (NASDAQ:TLSI), an oncology company dedicated to improving outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and our investigational immunotherapy, today announced key updates to its executive leadership team. James (Jim) Young, who previously served as the Company's Senior Vice President of Investor Relations and Treasurer, has been appointed as the Company's Chief Financial Officer. In this role, Mr. Young succeeds Sean Murp

      1/8/25 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

      TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, has announced the addition of Riad Salem, M.D., to its Scientific Advisory Board (SAB). Dr. Salem is the Chief of Interventional Radiology, and a Professor of Radiology, Surgery, and Medicine in Chicago. Mary Szela, Chief Executive Officer and President of TriSalus, stated, "We are thrilled to welcome Dr. Salem to our SAB. His pioneering work in radiological research and leadership in developing innovative treatments for liver cancer and other

      9/26/24 7:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Young James Emmett bought $33,900 worth of shares (6,000 units at $5.65) (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      2/6/25 6:09:01 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • CEO AND PRESIDENT Szela Mary T bought $51,754 worth of shares (10,040 units at $5.15), increasing direct ownership by 2% to 444,259 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      1/31/25 5:54:39 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • CEO AND PRESIDENT Szela Mary T was granted 40,000 shares and bought $50,303 worth of shares (9,542 units at $5.27), increasing direct ownership by 13% to 434,219 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      1/29/25 6:15:05 PM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on TriSalus Life Sciences

      Lake Street initiated coverage of TriSalus Life Sciences with a rating of Buy

      2/13/25 8:48:50 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • Cantor Fitzgerald initiated coverage on TriSalus Life Sciences with a new price target

      Cantor Fitzgerald initiated coverage of TriSalus Life Sciences with a rating of Overweight and set a new price target of $10.00

      12/17/24 8:31:30 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • ROTH MKM initiated coverage on TriSalus Life Sciences with a new price target

      ROTH MKM initiated coverage of TriSalus Life Sciences with a rating of Buy and set a new price target of $11.00

      11/11/24 7:48:55 AM ET
      $TLSI
      Medical Specialities
      Health Care